Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, James N. Kochenderfer, Jesús G. Berdeja et al.|New England Journal of Medicine|2019Cited by 1.7k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J. Nastoupil, Frederick L. Locke, Michael D. Jain et al.|Journal of Clinical Oncology|2020Cited by 782
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathEli Muchtar, Angela Dispenzieri, S. Vincent Rajkumar et al.|Blood|2017Cited by 340
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteriaArjun Lakshman, Shaji Kumar, S. Vincent Rajkumar et al.|Blood Cancer Journal|2018Cited by 288
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapySushanth Gouni, Paolo Strati, Allison Rosenthal et al.|Blood Advances|2022Cited by 37